Urgent surgery for RD gives best post-op VA

Article

Urgent vitrectomy/phacovitrectomy to treat retinal detachment will produce the best postoperative visual acuity when it is conducted within 2 days or less of the detachment, according to a recent study.

Urgent vitrectomy/phacovitrectomy to treat retinal detachment will produce the best postoperative visual acuity when it is conducted within 2 days or less of the detachment (RD), according to a study in the Asia-Pacific Journal of Ophthalmology.

Researchers conducted a retrospective, noncomparative, interventional case series of 56 eyes with macula-on RD and 126 eyes with bullous macula-off RD.

When the duration of macula detachment was 2 days or less, approximately 90% of eyes achieved a postoperative 20/40 best-corrected visual acuity (BCVA). Between 2 and 10 days, the ratio of eyes achieving BCVA of 20/40 decreased (P = 0.008), plateauing around 40%. Mean BCVA showed a statistically significant decrease when the time from the RD to the vitrectomy/phacovitrectomy exceeded 10 days (P = 0.009).

"An increasing number of ophthalmologists are using vitrectomy as the first line of treatment for retinal detachment," the researchers said. "To achieve a good postoperative visual acuity, urgent surgery with a duration of macular detachment of 2 days or less is desired. Operative repair within this period, rather than outright emergency surgery, may be appropriate for most cases."

To view the abstract of this study, click here.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.